Dr Reddys Laboratories RDY Revenue Breakdown

NYSE RDY
$14.70 -0.04 (-0.27%)
At close: Nov 16, 2026 · 4:00 PM EST
Annual revenue breakdowns for Dr Reddys Laboratories, fiscal 2016 to 2026, as reported in its filings.
Annual history

Dr Reddys Laboratories Revenue by Products And Services

Years FY 2021–2026
Lines 15
FY 2026 Total $333.81B

Oncology was Dr Reddys Laboratories’s largest revenue line in fiscal 2026, bringing in $68.31B of $333.81B (20%).

Dr Reddys Laboratories revenue by products and services, fiscal 2021 to 2026
Products And Services FY 2021 FY 2023 FY 2024 FY 2025 FY 2026
Oncology $52.92B $71.12B $89.20B $68.31B
Central Nervous System $31.64B $32.67B $47.07B $65.38B
Pain Management $27.31B $28.21B $31.22B $34.04B
Gastrointestinal $24.50B $24.48B $26.54B $28.54B
Cardiovascular $22.81B $24.21B $25.61B $26.43B
Other Global Generics $12.03B $21.60B $27.55B $23.68B
Respiratory $17.88B $17.23B $17.70B $22.41B
Anti-Infective $17.07B $15.90B $12.77B $13.20B
Hematology $10.74B $11.60B $11.09B $10.10B
Diabetology $5.89B $6.95B $9.49B $14.24B
Dermatology $7.47B $6.54B $7.17B $8.69B
Nutraceutical $5.88B $7.69B $9.13B $8.02B
Other Psai $3.71B $5.25B $6.78B $8.56B
Anti Infective One $2.35B $1.46B $1.68B $1.74B
Genitourinary $637.00M $367.00M $416.00M $475.00M
Total $242.84B $275.25B $323.40B $333.81B

Dr Reddys Laboratories revenue by products and services: what the figures show

Dr Reddys Laboratories brought in $333.81B from its 15 revenue lines in fiscal 2026, the year ended March 31, 2026. That was up 3.2% from $323.40B in fiscal 2025. Oncology was the largest at $68.31B (20.5%), ahead of Central Nervous System at $65.38B (19.6%) and Pain Management at $34.04B (10.2%). The other 12 revenue lines brought in $166.08B combined.

Compared with fiscal 2025, Diabetology grew fastest, up 50.0% to $14.24B, while Oncology fell the most, down 23.4% to $68.31B. From fiscal 2023 to 2026, combined revenue from these revenue lines grew from $242.84B to $333.81B, a compound annual growth rate of 11.2%. Oncology's share of the total fell from 21.8% to 20.5%.

Annual history

Dr Reddys Laboratories Revenue by Geography

Years FY 2016–2026
Lines 4
FY 2026 Total $335.93B

Others was Dr Reddys Laboratories’s largest region in fiscal 2026, bringing in $118.72B of $335.93B (35%).

Dr Reddys Laboratories revenue by geography, fiscal 2016 to 2026
Geography FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
United States $106.68B $135.57B $149.35B $117.89B
Others $67.47B $72.83B $94.40B $118.72B
India $50.50B $48.47B $55.83B $64.54B
Russia $21.23B $22.30B $25.96B $34.79B
Total $245.88B $279.16B $325.54B $335.93B
Totals include 2 discontinued lines from earlier reporting.

Dr Reddys Laboratories revenue by geography: what the figures show

Dr Reddys Laboratories brought in $335.93B from its four regions in fiscal 2026, the year ended March 31, 2026. That was up 3.2% from $325.54B in fiscal 2025. Others was the largest at $118.72B (35.3%), ahead of United States at $117.89B (35.1%) and India at $64.54B (19.2%). The remaining region, Russia, brought in $34.79B.

Compared with fiscal 2025, Russia grew fastest, up 34.0% to $34.79B, while United States fell the most, down 21.1% to $117.89B. From fiscal 2023 to 2026, combined revenue from these regions grew from $245.88B to $335.93B, a compound annual growth rate of 11.0%. Others' share of the total rose from 27.4% to 35.3%.

Annual history

Dr Reddys Laboratories Revenue by Segments [axis]

Years FY 2016–2026
Lines 3
FY 2026 Total $335.93B

Global Generic was Dr Reddys Laboratories’s largest segment in fiscal 2026, bringing in $299.03B of $335.93B (89%).

Dr Reddys Laboratories revenue by segments [axis], fiscal 2016 to 2026
Segments [axis] FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Global Generic $213.77B $245.45B $289.55B $299.03B
Pharmaceutical Services & Active Ingredient $29.07B $29.80B $33.85B $34.77B
Other Segment $3.04B $3.91B $2.14B $2.13B
Total $245.88B $279.16B $325.54B $335.93B
Totals include 2 discontinued lines from earlier reporting.

Dr Reddys Laboratories revenue by segments [axis]: what the figures show

Dr Reddys Laboratories brought in $335.93B from its three segments in fiscal 2026, the year ended March 31, 2026. That was up 3.2% from $325.54B in fiscal 2025. Global Generic was the largest at $299.03B (89.0%), ahead of Pharmaceutical Services & Active Ingredient at $34.77B (10.4%) and Other Segment at $2.13B (0.6%).

Compared with fiscal 2025, Global Generic grew 3.3% to $299.03B and Pharmaceutical Services & Active Ingredient grew 2.7% to $34.77B. From fiscal 2023 to 2026, combined revenue from these segments grew from $245.88B to $335.93B, a compound annual growth rate of 11.0%. Global Generic's share of the total rose from 86.9% to 89.0%.

Questions

Dr Reddys Laboratories Revenue Breakdown FAQ

How does Dr Reddys Laboratories make money?

Dr Reddys Laboratories (RDY) reports its revenue by products and services, by geography and by segments [axis]. In fiscal 2026, Oncology was its largest revenue line, bringing in $68.31B (20.5% of the total), followed by Central Nervous System at $65.38B (19.6%).

What is Dr Reddys Laboratories' largest revenue line?

Oncology was Dr Reddys Laboratories' largest revenue line in fiscal 2026, bringing in $68.31B, or 20.5% of the $333.81B total across its 15 revenue lines.

What is Dr Reddys Laboratories' largest region?

Others was Dr Reddys Laboratories' largest region in fiscal 2026, bringing in $118.72B, or 35.3% of the $335.93B total across its four regions.

What is Dr Reddys Laboratories' largest segment?

Global Generic was Dr Reddys Laboratories' largest segment in fiscal 2026, bringing in $299.03B, or 89.0% of the $335.93B total across its three segments.

Which Dr Reddys Laboratories revenue line is growing the fastest?

Among Dr Reddys Laboratories' revenue lines that make up at least 2% of revenue, Diabetology grew fastest in fiscal 2026, up 50.0% from $9.49B to $14.24B.

Where does this revenue breakdown data come from?

Every figure comes from Dr Reddys Laboratories' annual financial filings, as reported. Each line keeps the name Dr Reddys Laboratories gives it, and years follow its fiscal calendar.

How far back does Dr Reddys Laboratories' revenue breakdown go?

Dr Reddys Laboratories' revenue by products and services goes back to fiscal 2021, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.